交易 Filana Therapeutics Inc - FLNA 差價合約
Cassava Sciences Inc. (NASDAQ: SAVA) is a clinical-stage biotech company focused on developing Simufilam, an oral drug candidate for Alzheimer’s disease. Its platform is based on stabilizing a scaffolding protein (filamin A) thought to disrupt Alzheimer’s pathology. While the company faces scientific scrutiny and clinical trial volatility, it continues to advance large-scale Phase 3 studies. Cassava offers speculative exposure to high-stakes neurodegeneration treatment development with transformative, albeit controversial, upside potential.最新股票文章
收息股：股息率分布、選股風險框架與高息ETF配置分析
2026年港股收息股與高息ETF的股息率結構、派息可持續性風險、估值環境及行業分散配置邏輯，涵蓋銀行股、REITs、公用事業及能源板塊的風險收益特徵分析
08:35, 27 3月 2026
平頭哥分拆上市分析：阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市，摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度，解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026
評級和評論
評級和評論
